Joshua Weese, MD
Hematology & Oncology · Roseburg, ORNPI 1114123601
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. Onmark, Inc. accounts for 74.3% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $3,800, more than ten times the $34 reported in 2019.
Across 72 payments — averaging $66.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Onmark, Inc.$4K
- Johnson & Johnson$172
- Sanofi$108
- Novartis$103
- Pfizer$88
- Merck$85
- plus $681 from 19 others
What the payments were for
- Travel & lodging$2,11044%
- Food & beverage$2,45851%
- Education$2175%
- Gifts$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Onmark, Inc. | 10 | $3,568 |
| Johnson & Johnson | 7 | $172 |
| Sanofi | 6 | $108 |
| Novartis | 5 | $103 |
| Pfizer | 5 | $88 |
| Merck | 4 | $85 |
| AVEO Pharmaceuticals, Inc. | 4 | $81 |
| Amgen | 3 | $71 |
| Gilead(2 entities) | 4 | $62 |
| E.r. Squibb & Sons, L.L.C. | 3 | $61 |
| Puma Biotechnology, Inc. | 3 | $54 |
| GSK | 2 | $44 |
| Eisai Inc. | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 1 | $36 |
| Bristol Myers Squibb | 2 | $35 |
| Genentech USA, Inc. | 2 | $33 |
| Exelixis Inc. | 1 | $24 |
| Myovant Sciences Inc. | 1 | $23 |
| EMD Serono, Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $19 |
| Tersera Therapeutics LLC | 1 | $18 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $17 |
| Array Biopharma Inc | 1 | $16 |
| Spectrum Pharmaceuticals Inc. | 1 | $16 |
| AbbVie | 1 | $14 |
How this compares
$4,805 in reported general payments places this provider in the 75th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 71 | $1,013,343 |
| RevlimidLenalidomide | 34 | $432,535 |
| JakafiRuxolitinib Phosphate | 22 | $367,034 |
| DopteletAvatrombopag Maleate | 12 | $277,066 |
| VerzenioAbemaciclib | 19 | $266,306 |
| TagrissoOsimertinib Mesylate | 15 | $250,278 |
| ImbruvicaIbrutinib | 15 | $242,948 |
| IbrancePalbociclib | 15 | $240,632 |
| CalquenceAcalabrutinib Maleate | 16 | $237,072 |
| XtandiEnzalutamide | 12 | $172,173 |
| NubeqaDarolutamide | 12 | $163,103 |
| Abiraterone Acetate | 31 | $107,730 |
| XareltoRivaroxaban | 37 | $34,292 |
| Anastrozole | 202 | $4,546 |
| Fentanyl | 35 | $2,926 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $35 | $432,53534 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $17 | $242,94815 claims |
| PfizerIbrance | $88 | $240,63215 claims |
| Johnson & JohnsonXarelto | $172 | $34,29237 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 112 hematology & oncology providers in Oregon.
Other hematology & oncology in Roseburg
- Edward OttenheimerRoseburg$5K
- Stephen WilliamsRoseburg$5K
- Brian DrukerPortland$1.9M
- Bo WangCorvallis$251K
- Jay AndersenPortland$196K
- Richard MaziarzPortland$174K
- Tibor KovacsovicsPortland$119K
- Christopher YasenchakEugene$102K
- Elie TraerPortland$72K
- Luke FletcherEugene$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.